A Study to Evaluate the Efficacy & Safety of an Intra-Articular Ampion Injection for Pain of Osteoarthritis of the Knee

• Status: Completed
• Trial end date: 2016-06-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the efficacy and safety of an intra-articular injection of AMPION™ in adults with pain due to osteoarthritis of the knee

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ampio Pharmaceuticals. Inc.

Criteria

Inclusion Criteria:

• Able to provide written informed consent to participate in the study;

• Willing and able to comply with all study requirements and instructions of the site study staff;

• Male or female, 40 years to 85 years old (inclusive);

• Must be ambulatory;

• Index knee must be symptomatic for greater than 6 months with a clinical diagnosis of OA and supported by radiological evidence (Kellgren Lawrence Grade II, III, or IV) read by a central reader;

• WOMAC 5-point Likert pain subscale <1.5 in the contralateral knee;

• Moderate to moderately-severe OA pain in the index knee (rating of at least 1.5 on the WOMAC Index 3.1 5-point Likert Pain Subscale);

• Moderate to moderately-severe OA pain in the index knee (even if chronic doses of nonsteroidal anti-inflammatory drug (NSAID), which have not changed in the 4 weeks prior to screening, have been/are being used);

• Ability to discontinue NSAID use at Screening visit and/or 72 hours prior to the Baseline visit and for the duration of the clinical study (low dose Aspirin is allowed during the study);

• No analgesia (including acetaminophen [paracetamol]) taken 24 hours prior to an efficacy measure;

• No known clinically significant liver abnormality (e.g. cirrhosis, transplant, etc.).

Exclusion Criteria:

• As a result of medical review and screening investigation, the Principal Investigator considers the patient unfit for the study

• A history of allergic reactions to human albumin (reaction to non-human albumin such as egg albumin is not an exclusion criterion)

• A history of allergic reactions to excipients in 5% human albumin (N-acetyltryptophan, sodium caprylate)

• Presence of tense effusions

• Inflammatory or crystal arthropathies, acute fractures, history of aseptic necrosis or joint replacement in the affected knee, as assessed locally by the Principal Investigator

• Isolated patella femoral syndrome, also known as chondromalacia

• Any other disease or condition interfering with the free use and evaluation of the index knee for the duration of the trial (e.g. cancer, congenital defects, spine osteoarthritis)

• Major injury to the index knee within the 12 months prior to screening

• Severe hip osteoarthritis ipsilateral to the index knee

• Any pain that could interfere with the assessment of index knee pain (e.g. pain in any other part of the lower extremities, pain radiating to the knee)

• Any pharmacological or non-pharmacological treatment targeting OA started or changed during the 4 weeks prior to randomization or likely to be changed during the duration of the study

• Pregnancy or planning to become pregnant during the study.

• Use of the following medications:

• No IA injected pain medications in the study knee during the study

• No analgesics containing opioids.

• NSAIDs are not permitted during the study; acetaminophen is available as a rescue medication during the study from the provided supply.

• No topical treatment on osteoarthritis index knee during the study

• No significant anticoagulant therapy (e.g. Heparin or Lovenox) during the study (treatment such as low dose Aspirin and Plavix are allowed)

• No systemic treatments that may interfere with safety or efficacy assessments during the study

• No immunosuppressants

• No use of corticosteroids

• No human albumin treatment in the 3 months before randomization or throughout the duration of the study